Not Signed In -
Ropivacaine |
Naropin |
Clinical Trial: Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery
This study has been completed.
|
Purpose
Compare lumbar plexus block with ropivacaine 0.475%, 0.4 ml/kg to saline. Each group randomized, includes 30 patients. block performed preoperatively Surgery under general anesthesia. Postoperative evaluation of pain (VAS) as first endpoint, and also morphine consumption via PCA device. Follow-up : 24h.
Expectation : sizeable reduction of pain with block, of duration.
| Condition | Intervention |
|---|---|
| Pain Postoperative | Drug: ropivacaine |
MedlinePlus related topics: Pain
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Study of Posterior Lumbar Plexus Block for Pain Relief After Hip Surgery
Secondary Outcomes: decrease in morphine consumption; duraration of analgesic effect
Expected Total Enrollment: 60
Study start: September 2001; Study completion: August 2002
Last follow-up: March 2002; Data entry closure: March 2002
Compare lumbar plexus block (randomized)
- ropivacaine 0.475%, 0.4 ml/kg
- saline 0.4 ml/kg . Each group includes 30 patients.
Block performed preoperatively.
Surgery under general anesthesia (sufentanil, propofol, atracurium ; maintenance : sevoflurane and nitrous oxide in O2. Sufentanil added peroperatively as clinically needed.
Postoperative evaluation of pain (VAS, by an independant blind observer) as first endpoint, and also morphine consumption via PCA device.
Adverse effects (nausea, vomiting, etc) recorded
Follow-up : 24h. Expectation : sizeable reduction of pain with block, of duration.
Eligibility
Inclusion Criteria:
- adults
- ASA 1-3
Exclusion Criteria:
- cognitive impairement
- ASA IV
Location Information
laurent beydon, MD, Study Director, CHU d''''ANGERS
ibrahim okais, MD, Principal Investigator, Clinique St Leonard
More Information
Last Updated: September 7, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00150865
Health Authority: France: Afssaps - French Health Products Safety Agency
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
